Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CORLUX (mifepristone) for Endogenous Cushing's Syndrome
NCT01371565Phase 3
Key facts
- Status
- Completed
- Start
- Nov 2010
- Primary completion
- Jun 2012
- Countries
- 1
- Sponsor
- Corcept Therapeutics
- Modality
- Orthosteric Ligands
- Drugs
- mifepristone
- Conditions
- Cushing's syndrome
01
Overview
Phase 3, open-label, single-arm trial of mifepristone in Cushing's syndrome, sponsored by Corcept Therapeutics. Primary endpoint: Adverse Events at 6 months. Started Nov 2010; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Mifepristone Arm
Open-label administration of mifepristone for 6 months
03
Who it enrols
Patients with confirmed endogenous hypercortisolemia (Cushing's Disease, Ectopic ACTH, Adrenal adenoma/carcinoma) who require medical treatment and have failed or are not candidates for surgery.
04
Endpoints
Primary
Adverse Events
Beyond the preview
Go deeper on NCT01371565.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01371565.